Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Clinical trial NCT05280509 · RECRUITING

Trial details

NCT number: NCT05280509
Sponsor: Telios Pharma, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelofibrosis Primary Myelofibrosis Post-PV MF Post-ET Myelofibrosis

Start date: 2022-06-09
Primary completion: 2025-10-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.